Article type:
Research
Estimated read time:
3 mins min read
Published:
11/11/2025
This study explores how changes in gut bacteria (microbial dysbiosis) can lead to inflammation in diseases like (stimulator of interferon genes) STING-associated vasculopathy with onset in infancy (SAVI) and systemic lupus erythematosus (SLE). It found that certain markers (cyclic dinucleotides) related to these bacteria are higher in affected patients. This research helps us understand how gut health affects autoimmune diseases and could lead to better treatments in the future.
Why it Matters Understanding the interplay between gut microbiota and STING-driven inflammation is crucial for several reasons:
- Disease Mechanism Insights: It provides insights into the pathogenesis of autoimmune diseases, potentially leading to more targeted therapies.
- Biomarker Development: Identifying microbial CDNs as specific biomarkers could improve diagnostic accuracy and personalized treatment strategies for patients with autoimmune conditions.
- Therapeutic Implications: The findings may inform new therapeutic approaches that target gut microbiota to modulate inflammatory responses in autoimmune diseases.
Hope for the Future The study opens several avenues for future research:
- Microbiome Modulation: Investigating interventions that may restore healthy gut microbiota as a therapeutic strategy for managing autoimmune diseases.
- Understanding Disease Heterogeneity: Further studies are needed to clarify the heterogeneity of autoimmune conditions and the role of STING activation in different patient subgroups.
- Potential for New Treatments: The development of treatments that can manipulate cyclic dinucleotide pathways or gut microbiota might offer novel approaches to manage inflammation in autoimmune diseases.
Read more
Background The study focuses on the relationship between microbial dysbiosis and the autoinflammatory responses driven by cyclic dinucleotides (CDNs) in conditions such as SAVI and SLE. It highlights the critical role of gut microbiota in disease pathogenesis and how alterations in microbial composition can influence inflammatory processes. The findings are particularly relevant for understanding immune-mediated diseases where STING activation plays a significant role.
What the Study Found
- Dysbiosis in SAVI Mice: Mice with SAVI exhibited significant gut microbiota dysbiosis, with reduced levels of short-chain fatty acid-producing bacteria and increased segmented filamentous bacteria.
- Elevated Faecal CDNs: There were higher faecal CDN levels in SAVI mice, indicating a link between dysbiosis and STING-mediated auto-inflammation.
- Human Correlation: In SLE patients, plasma levels of host- and microbial-derived CDNs were significantly higher compared to healthy controls, suggesting a similar dysbiotic profile.
- Type I IFN Activity: A correlation was found between microbial CDNs and type I interferon (IFN) activity in SLE patients, particularly regarding anti-dsDNA antibody levels.
- Negative Findings: Serum CDN levels did not show a significant elevation across all SLE patients compared to healthy controls, indicating that not all SLE cases are STING-dependent.
- Biomarker Potential: The study suggests that while systemic CDNs may not be universal diagnostic markers, they could serve as biomarkers for disease activity in specific STING-activated subgroups.
Citation Shibahara et al., J Autoimmun 2025, 154, 103434
Authors Takayuki Shibahara, Burcu Temizoz, Shiori Egashira, Koji Hosomi, Jonguk Park, Naz Surucu, Albin Björk, Erdal Sag, Takehiko Doi, Rabia Miray Kisla Ekinci, Sibel Balci, Marjan A Versnel, Jun Kunisawa, Masahiro Yamamoto, Tomoya Hayashi, Shuichi Ito, Yuji Kamiyama, Kouji Kobiyama, Peter D Katsikis, Cevayir Coban, Mayda Gursel, Seza Ozen, Sumiyuki Nishida, Atsushi Kumanogoh, Ken J Ishii
Date of publication 6/5/25